Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]


On page 1027, please note that on Table 1, the population for the trial GOG170D (Burger et al\textsuperscript{34}) with 62 patients was described as “\(\leq 2\) lines of previous treatment, 58\% PI resistant, 26\% PI sensitive with PI-free interval <12 months”. However, the correct description of the population should be “\(\leq 2\) lines of previous treatment, 58\% PI resistant, 42\% PI sensitive”.

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]